Human immunodeficiency virus type 1 (HIV-1), introduced into the brain by HIV-1-infected monocytes which migrate across the blood-brain barrier (BBB), infects resident macrophages and microglia and initiates a process that causes HIV-1-associated neurocognitive disorders. The mechanism by which HIV-1 infection circumvents the BBB-restricted passage of systemic leukocytes into the brain and disrupts the integrity of the BBB is not known. Circulating lipopolysaccharide (LPS), which can compromise the integrity of the BBB, is significantly increased in HIV-1-infected individuals. We hypothesized that HIV-1 infection increases monocyte capacity to migrate across the BBB, which is further facilitated by a compromise of BBB integrity mediated by the increased systemic LPS levels present in HIV-1-infected individuals. To investigate this possibility, we examined the in vivo BBB migration of monocytes derived from our novel mouse model, JR-CSF/EYFP mice, which are transgenic for both a long terminal repeat-regulated full-length infectious HIV-1 provirus and ROSA-26-regulated enhanced yellow fluorescent protein. We demonstrated that JR-CSF/EYFP mouse monocytes displayed an increased capacity to enter the brain by crossing either an intact BBB or a BBB whose integrity was partially compromised by systemic LPS. We also demonstrated that the JR-CSF mouse BBB was more susceptible to disruption by systemic LPS than the control wild-type mouse BBB. These results demonstrated that HIV-1 infection increased the ability of monocytes to enter the brain and increased the sensitivity of the BBB to disruption by systemic LPS, which is elevated in HIV-1-infected individuals. These mice represent a new in vivo system for studying the mechanism by which HIV-1-infected monocytes migrate into the brain.
Human immunodeficiency virus type 1 (HIV-1) enters the brain during the establishment and systemic dissemination of HIV-1 infection and either directly or indirectly causes a broad range of HIV-1-associated neurocognitive disorders, including asymptomatic neurocognitive impairment, HIV-1-associated mild neurocognitive disorder, and HIV-1-associated dementia (HAD) (6) . HAD, a devastating neurological disease that is a frequent consequence of HIV-1 infection (42, 43) , is associated with the pathological findings of HIV-1 encephalitis, characterized by multinucleated giant-cell formation, microglial nodules, astrogliosis, myelin pallor, and neocortical atrophy (48) . The major route by which HIV-1 enters the brain is transmigration of HIV-1-infected monocytes across the blood-brain barrier (BBB) early in the course of infection (23, 27, 36, 44) . After entry into the brain, these peripheral HIV-1-infected monocytes produce HIV-1 that subsequently infects resident brain microglia and macrophages (3, 7, 37, 38, 66) . HAD is not caused by direct HIV-1 infection of neurons but rather is a consequence of the cumulative neurotoxic effects of multiple factors produced by HIV-1-infected or HIV-1-exposed cells in the brain, such as microglia and macrophages (33, 48, 67) .
Circulating monocytes are normally precluded from migrating into the brain by the BBB, an anatomical barrier that restricts the exchange of cells and soluble factors from the blood into the brain parenchyma (47, 57) . The BBB is composed of several components that include specialized endothelial cells which form tight junctions at cellular contact points, the end feet of astrocytes that surround the blood vessels, the capillary basement membrane, and pericytes which are embedded in the basement membrane (31) . The BBB prevents migration of inflammatory cells from the periphery into the brain, with the exception of a small number of leukocytes engaged in immune surveillance that can pass across the BBB without altering BBB integrity. The restricted passage of leukocytes from the systemic circulation into the brain across the BBB may be disrupted during the course of HIV-1 infection (53, 54) . Compromise of the integrity of the BBB allows circulating HIV-1-infected monocytes to enter the brain, which further disrupts BBB integrity and permits the influx into the brain of more HIV-1-infected monocytes; this further disrupts BBB integrity and allows the entry of increased numbers of HIV-1-infected monocytes, which subsequently infect resident brain monocytes and microglia with HIV-1 (23, 25) . The precise mechanism by which HIV-1-infected monocytes cross the intact BBB and subsequently disrupt the integrity of the BBB is not known.
The plasma of HIV-1-infected individuals contains markedly elevated levels of lipopolysaccharide (LPS) due to the in-creased microbial translocation across a gut mucosa barrier which is compromised by HIV-1-mediated depletion of mucosal CD4 T lymphocytes (11, 22 ). The mean LPS plasma level (75 pg/ml) in HIV-1 progressors is markedly higher than the plasma level of LPS (14 pg/ml) shown to activate the systemic immune system and induce inflammatory cytokine production in LPS-injected HIV-1-naive human volunteers (22) and was associated with in vivo activation of the innate and adaptive immune systems of HIV-1 progressors (11, 22) . The in vivo integrity of the BBB can be compromised by exposure to elevated levels of LPS in the circulation (70) . We hypothesized that the increased levels of systemic LPS in HIV-1-infected individuals disrupt BBB integrity and permit the influx of increasing numbers of HIV-1-infected monocytes, which further compromise BBB integrity, and permit the entry of increasing numbers of HIV-1-infected monocytes, which ultimately initiates the development of HAD. We also postulated that HIV-1 infection of monocytes may increase their capacity to migrate across the intact and partially compromised BBB. An in vitro model of the BBB that consists of brain microvascular endothelial cells and astrocytes cultured on opposite sides of a semipermeable coated membrane has permitted investigation of the mechanism by which HIV-1-infected monocytes cross and damage the BBB (52, 68) . Although this model has been very useful for studying some aspects of BBB function, it does not fully recapitulate the in vivo function of the BBB. As an in vivo model to investigate whether HIV-1-infection alters the capacity of monocytes to cross the intact BBB and whether HIV-1 infection increases the sensitivity of the BBB to disruption by systemic LPS, we used our well-characterized system consisting of JR-CSF mice, which are transgenic for an infectious HIV-1 provirus (13, 46, 64) .
Our JR-CSF transgenic mouse line circumvents the block of HIV-1 entry into mouse cells by carrying as a transgene a full-length infectious HIV-1 provirus derived from the primary R5-tropic clinical isolate HIV-1 JR-CSF , and these mice display plasma viremia at levels comparable to that observed in HIV-1-infected patients (46, 64) . Furthermore, infectious HIV-1 is produced by monocytes and microglia from the JR-CSF mice, and LPS-stimulated JR-CSF mouse monocytes and microglia produce higher levels of MCP-1 than monocytes and microglia from LPS-stimulated control mice (65) . Because JR-CSF mouse monocytes and microglia carry an HIV-1 provirus regulated by the HIV-1 long terminal repeat, we used this model to investigate whether HIV-1 infection of monocytes increases their in vivo capacity to cross the intact and LPS-compromised BBB and migrate into the brain. In the current study, we demonstrated that monocytes from JR-CSF mice displayed an increased capacity to cross both the intact and compromised BBB into the brain parenchyma and that the BBB of JR-CSF mice is more susceptible to disruption by inflammatory signals, such as LPS, than that of control wild-type (WT) mice.
MATERIALS AND METHODS
Construction of mice transgenic for HIV-1 JR-CSF and EYFP genes. The JR-CSF transgenic mouse line was constructed using a plasmid containing an infectious molecular clone of HIV-1 JR-CSF (PYK-JR-CSF, obtained from the NIH AIDS Research and Reference Reagent Program), that was cloned from the lymphocytes of an HIV-1-infected patient soon after the initiation of culture (13) . This construct contains the full-length genomic sequence of HIV-1 JR-CSF , as well as 0.5 kb of 3Ј and 2.2 kb of 5Ј flanking sequences, and produces infectious virions after transfection into cells (15, 45) . The PYK-JR-CSF plasmid was linearized with EcoRI and microinjected into the pronuclei of fertilized embryos derived from F1 FVB ϫ C57/B6 mouse crosses as described previously (12) . R26-EYFP mice, which ubiquitously express enhanced yellow fluorescent protein (EYFP), were obtained from Frank Costantini (60) and crossed with JR-CSF mice to generate transgenic mice which carry both the JR-CSF and EYFP transgenes (JR-CSF/EYFP mice). Offspring were screened by PCR analysis of genomic DNA extracted from tail DNA using primer pairs specific for amplification of HIV-1 Gag DNA (13) and EYFP genes (16 (39) , and passed through a positive selection autoMACS separation column using the AutoMACS automated bench-top magnetic cell sorter (Miltenyi Biotec Inc., Auburn, CA) as described previously (61) . The purity of the sorted cells was determined by flow cytometry, and greater than 90% of the positively selected cells expressed CD11b. Intravenous injection of EYFP or JR-CSF/EYFP monocytes and intraperitoneal injection of LPS. Highly purified monocytes (5 ϫ 10 6 cells) that were isolated from the bone marrow of R26-EYFP or JR-CSF/EYFP transgenic mice as described above were intravenously injected into the tail veins of 1-to 2-month-old mice after they were anesthetized with pentobarbital (40 to 80 mg/kg of body weight). Some mice were intraperitoneally injected with LPS (3 mg/kg) from Escherichia coli 0111:B4 (Sigma, St. Louis, MO) 3 hours before intravenous injection with the mouse monocytes (5 ϫ 10 6 cells). After 4 days, the mice were anesthetized, exsanguinated, and intracardially injected with 10 ml of PBS to flush the residual blood from the circulation, and their brains and spleens were harvested and analyzed.
Detection by PCR of R26-EYFP or JR-CSF/EYFP mouse monocytes in peripheral blood, spleens, and brains of injected mice. DNA was extracted from the mouse brains, spleens, or peripheral blood (500 l) using the Easy-DNA kit (Invitrogen Corporation, Carlsbad, CA) according to the manufacturer's instructions and resuspended in 150 l Tris-EDTA buffer. The concentration of DNA samples was determined using a Smartspec 3000 spectrophotometer (Bio-Rad), and equivalent DNA concentrations for each sample were analyzed by PCR. The presence of R26-EYFP monocytes and JR-CSF/EYFP monocytes in the tissues of the injected mice was detected by PCR amplification using 10 l genomic DNA as the template for the first round (40 cycles at 94°C for 30 s, 60°C for 1 min, and 72°C for 1 min). In some studies, we increased the sensitivity for detection of EYFP DNA by using 5 l from the first round of PCR amplification as a template for a second PCR amplification of 40 cycles using the same amplification protocol. Taq platinum polymerase (Invitrogen Corporation, Carlsbad, CA) and EYFP-specific primers (5Ј-TACGGCAAGCTGACCCTGAAGT TC-3Ј and 5Ј-CGTCCTTGAAGATGGTGCG-3Ј) were added to the PCR mix, and the amplimers were detected by gel electrophoresis as described previously (30) . No PCR products were detected after either the first-or second-round PCR amplifications of control mouse DNA with these primer pairs, which confirmed the specificity of the PCR. To provide a reference standard for semiquantitative measurement of the EYFP DNA concentration, a region in exon 2 of the mouse exonuclease 1 gene was amplified (30 cycles at 94°C for 30 s, 56°C for 1 min, and 72°C for 1 min) from 5 l DNA samples from the indicated tissues or blood using exonuclease gene-specific primers (5Ј-GGGATTCAAGGGTTACTTCAGTT C-3Ј and 5Ј-TTTCAGCACAAGCAATAGCCC-3Ј). Semiquantitative measurement of the number of migrated cells in the brain was performed by comparing the densities of the EYFP amplimer bands to the densities of the exonuclease amplimer bands using the Kodak Image Station 440 analyzer system and Kodak 1D 3.5 image software (Eastman Kodak, Rochester, NY).
Visualization by fluorescence microscopy of EYFP-expressing cells in brains of mice injected with JR-CSF/EYFP mouse monocytes. Four days after injection of LPS-treated JR-CSF mice with JR-CSF/EYFP mouse monocytes, the mice were anesthetized and perfused by intracardiac injection with 0.9% NaCl followed by 4% paraformaldehyde. The brains were incubated for 24 h in 30% sucrose in PBS and snap-frozen in optimal-cutting-temperature compound as described previously (18) . Coronal cryostatic sections (10-m thickness) from the mid-coronal region of the brain were cut onto slides and coverslipped in one drop of mounting medium with 4Ј,6Ј-diamidino-2-phenylindole (Vector Laboratories, Inc., Burlingame, CA). Fluorescent JR-CSF/EYFP monocytes in the brain were detected and visualized by confocal fluorescence microscopy, and representative images were captured using a Nikon DN100 digital camera.
Evaluation of ZO-1 and occludin expression in brain vasculature. After mice were perfused by cardiac injection with PBS, their brains were removed, fixed in 10% buffered formalin, bisected coronally, and embedded in paraffin. Sections (5 m thick) were cut onto slides, deparaffinized in xylene, and rehydrated in serial ethanol solutions. After treatment with pepsin (ZYMED Laboratories) at 37°C for 10 min, the slides were incubated with sheep serum and bovine serum albumin blocking solution to eliminate nonspecific reactivity and then incubated with rabbit anti-zona occludens-1 (ZO-1) (ZYMED Laboratories) and goat antioccludin (Santa Cruz Biotechnology) at optimized concentrations. The slides were washed, incubated with sheep anti-rabbit immunoglobulin G Cy3-conjugated antibody (Sigma) and donkey anti-goat immunoglobulin G Cy5-conjugated antibody (Jackson ImmunoResearch Laboratories), washed again, and mounted with the Prolong Gold antifade reagent containing DAPI (4Ј6-diamidino-2-phenylindole) (Molecular Probes). The sections were analyzed for cerebral blood vessel occludin and ZO-1-specific fluorescence with a Leica AOBS laser scanning confocal microscope system, and representative images were captured using a Nikon DN100 digital camera.
RESULTS
JR-CSF/EYFP mouse monocytes but not control mouse monocytes cross the intact BBB into the brain. We previously demonstrated that bone marrow-derived monocytes from JR-CSF mice support HIV-1 replication, produce HIV-1 that infects activated human peripheral blood mononuclear cells in vitro (13) , and introduce disseminated HIV-1 infection in vivo into SCID mice implanted with pieces of human fetal thymus and liver (thy/liv-SCID-hu mice) (64) . We postulated that JR-CSF mouse monocytes that carry an integrated long terminal repeat-regulated HIV-1 provirus could be used to recapitulate the behavior of HIV-1-infected monocytes and enable us to study the process of in vivo migration of HIV-1-infected monocytes across the BBB into the brain. To establish a system where these migrant cells could be detected in the brains of recipient mice by PCR and fluorescence microscopy, we crossed the JR-CSF mice with R26-EYFP mice, which carry an EYFP gene under the control of the ubiquitously expressed ROSA26 promoter, to generate JR-CSF/EYFP mice which express both transgenes. To determine whether monocytes expressing HIV-1 proteins displayed an increased capacity to cross the intact BBB, JR-CSF/EYFP or R26-EYFP mouse monocytes (5 ϫ 10 6 cells) were intravenously injected into BALB/c SCID mice. Four days after injection of the monocytes, circulating leukocytes were flushed from the blood vessels of the mice by intracardiac injection of PBS, their brains were harvested, the meninges were removed, and their brain DNA was extracted. Carriage of the EYFP transgene permitted us to detect the presence of transferred JR-CSF/EYFP and R26-EYFP mouse monocytes in the brains of the recipient mice by PCR amplification with EYFP-specific primers of DNA extracted from the mouse brains. No EYFP DNA was detected in the brains of any of the injected mice after a single round of PCR. After a second round of PCR amplification, while no EYFP DNA was detected by PCR in any of the 10 BALB/c SCID mice injected with R26-EYFP mouse monocytes, EYFP DNA was detected by PCR in 3 of 10 BALB/c SCID mice injected with JR-CSF/EYFP mouse monocytes (Fig. 1) . Analysis of the brain DNA with PCR amplification using exonuclease-specific primers demonstrated that comparable levels of DNA were present in the brain samples analyzed. Variability in detection of EYFP DNA in the peripheral blood likely reflects the differential rate of in vivo clearance of the injected cells. These results indicated that HIV-1-infected monocytes display an increased capacity to cross an intact BBB and enter the brain.
JR-CSF/EYFP mouse monocytes and not control R26-EYFP mouse monocytes cross the BBB of LPS-treated BALB/c mice. Treatment of mice with a low dose of LPS (3 mg/kg) partially compromises the integrity of the BBB without disrupting the capillary structure (9, 69) , and this approach has been used to investigate the in vivo capacity of factors to modulate BBB permeability (1, 63) . We postulated that LPS-mediated compromise of the BBB is relevant to HIV-1 infection because the BBB in HIV-1-infected individuals may be partially compromised in a similar manner by their increased levels of LPS in plasma (11) . Therefore, we examined whether the JR-CSF/ EYFP mouse monocytes that support HIV-1 replication displayed an increased capacity to migrate across a BBB whose integrity was partially compromised by LPS and enter the brain. Three hours after BALB/c mice were intraperitoneally injected with LPS (3 mg/kg), the mice were intravenously injected with either R26-EYFP or JR-CSF/EYFP mouse monocytes (5 ϫ 10 6 cells). Four days later, the mouse brains were harvested and the DNA was extracted and analyzed with a single round of PCR with EYFP-specific primers (Fig. 2) . We did not detect passage of R26-EYFP mouse monocytes into the brains of any of the 15 BALB/c mice injected with R26-EYFP mouse monocytes. In contrast, we detected migration of JR-CSF/EYFP mouse monocytes into the brains of 4 of 15 BALB/c mice injected with JR-CSF/EYFP mouse monocytes. These results indicated that monocytes carrying the JR-CSF provirus displayed an increased capacity to cross a BBB whose integrity was partially compromised by LPS treatment.
The BBB in JR-CSF mice is more sensitive to disruption by systemic LPS. We previously demonstrated that HIV-1 replication occurs in the brains of JR-CSF mice (65) . We used these mice to examine whether systemic viremia and local production of HIV-1 proteins was associated with increased sensitivity of the BBB to disruption by LPS treatment, as indicated by increased migration of monocytes from the peripheral circulation into the brain. JR-CSF mice or BALB/c mice were intraperitoneally injected with LPS (3 mg/kg), and 3 h later the mice were injected with monocytes (5 ϫ 10 6 cells) isolated from JR-CSF/EYFP mice. After 4 days, the injected mice were sacrificed and their peripheral blood, spleens, and brains were analyzed for the presence of transferred monocytes by EYFPspecific PCR. PCR analysis of the brains of the LPS-treated BALB/c mice injected with JR-CSF/EYFP mouse monocytes demonstrated passage of JR-CSF/EYFP mouse monocytes into the brains of 3 out of 10 injected BALB/c mice (Fig. 3A) . In contrast, we detected passage of JR-CSF/EYFP mouse monocytes into the brains of 7 out of 10 injected JR-CSF mice (Fig. 3B) . The relative number of JR-CSF/EYFP mouse monocytes in the brains of the injected BALB/c or JR-CSF mice was determined by comparing the intensity of the EYFP-PCRamplified product detected in mouse brains normalized to the intensity of the exonuclease-specific PCR products of the brain DNA by densitometric analysis. Densitometric analysis of the PCR products detected in the mouse brains where JR-CSF mouse monocytes entered indicated that threefold-higher numbers of JR-CSF/EYFP mouse monocytes penetrated the 3C . Taken together, these results indicate that HIV-1-infected monocytes migrated across the BBB into the brain parenchyma, where they could potentially introduce HIV-1 infection and initiate neurotoxic processes.
Cerebral blood vessels in LPS-treated JR-CSF mice display increased disruption of BBB-specific cerebral vascular tight junctions. We investigated whether the functional evidence for increased compromise of BBB integrity indicated by the passage of monocytes into the brains of JR-CSF mice correlated with anatomical evidence of increased disruption of the BBB. The BBB is composed of tight junctions between epithelial cells formed by the interaction of continuous intramembranous strands of several proteins, including ZO-1 and occludin (20) . Anatomical compromise of the BBB due to HIV-1 infection could be detected by visualizing breaks in the intramembranous strands by immunohistological analysis of ZO-1 and occludin in cerebral blood vessels (20) . All of the cerebral FIG. 1. JR-CSF/EYFP monocytes migrate into the intact brain. DNA was extracted from brains, spleens, and blood of SCID mice 4 days after intravenous injection with either the EYFP monocytes or JR-CSF/EYFP monocytes. DNA extracted from an EYFP mouse or a WT mouse provide the positive or negative control, respectively. PCR amplification products from two rounds of PCR using primers specific for the EYFP gene or one round of PCR using mouse exonuclease gene-specific primers were resolved on an agarose gel containing ethidium bromide. Quantitative analysis of the EYFP-specific bands was done to determine the relative number of migrated cells in the brain. The number shown is the density of EYFP-specific bands normalized to the density of the exonuclease-specific bands in the indicated mouse brain. blood vessels in untreated WT and JR-CSF mice displayed strong and continuous interendothelial patterns of equivalent intensity of occludin and ZO-1, indicating the presence of an intact BBB (Fig. 4) . To determine if systemic treatment of mice with LPS more severely compromised the functional activity of the BBB in JR-CSF mice, we compared the effect of peripheral LPS injection on the integrity of ZO-1 and occludins in the cerebral vessels of JR-CSF mice to that for control BALB/c mice. In the brains of LPS-treated BALB/c mice, some cerebral vessels displayed intermittent breaks in occludin and ZO-1 continuity. In contrast, a markedly greater disruption of the anatomical BBB of the cerebral blood vessels in the LPStreated JR-CSF mice was observed, as indicated by the weak and fragmented expression of occludin and ZO-1 by the majority of cortical blood vessels (Fig. 4A) . Semiquantitative measurement of the extent of BBB integrity compromise in the brains of LPS-treated mice was performed as described previously (20) and demonstrated that significantly more vessels (P Ͻ 0.02) displayed BBB disruption in JR-CSF mouse brains than in BALB/c mouse brains (Fig. 4B) . Taken together, these results indicated that the BBB of JR-CSF mice was more susceptible to disruption by LPS than the BBB of WT mice.
DISCUSSION
Although HAD does not occur until several years after infection, several lines of evidence have indicated that the entry of HIV-1 into the brain occurs early in the course of infection (33) . Antibodies directed to HIV-1 envelope protein were detected in the cerebrospinal fluid of neurologically asymptomatic HIV-1-positive subjects (5, 29) , HIV-1 was isolated from the cerebrospinal fluid of asymptomatic HIV-1-positive individuals (17) , and HIV-1 viral particles (21) and HIV-1 DNA (2) were detected in the brains of asymptomatic HIV-1-positive subjects. Several observations support the critical role of migration of HIV-1-infected monocytes across the BBB into the brain as the major mechanism by which HIV-1 infection is introduced into the brain (19, 33, 36, 66) . First, the phenotype of the majority of HIV-1 isolated from the brain is monocyte tropic (28) . Second, HIV-1-infected cells detected in the brains of HIV-1-infected individuals are predominantly from the macrophage lineage (19, 35, 66) . Third, primate studies have indicated that the presence of monocyte-tropic strains in the central nervous system (CNS) is required for the development of simian immunodeficiency virus (SIV) encephalitis (4, 34, 59) . Fourth, the capacity of brain vessel endothelium to bind monocytes is greatly increased by SIV infection (58) . Finally, the perivascular presence of SIV-infected macrophages/microglia is detected in the brains of primates soon after infection with SIV (41) . Studies using an in vitro BBB model have demonstrated that greater numbers of HIV-1-infected monocytes than uninfected monocytes passed across a membrane coated with brain microvascular endothelial cells on one side and astrocytes on the other side (24, 52) . However, investigation of the mechanism by which HIV-1-infected monocytes migrate across the BBB from the peripheral circulation into the brain has been limited by the absence of an in vivo model of HIV-1 infection.
Although there are differences between the biological behaviors of murine and human mononuclear phagocytes such as microglia and macrophages, mouse models provide informative in vivo systems for studying BBB function and the deleterious effect of HIV-1 on the CNS. Knockout mouse models (55) , transgenic mouse models using tissue-specific promoters (14) , and experimental mouse models of CNS inflammation (26) have been used to delineate the mechanisms by which cells traffic across the BBB from the periphery and into the brain. Mouse models were developed to study HIV-1-induced neuropathology using SCID mice stereotactically injected with HIV-1-infected monocytes or microglia in their basal ganglia/ cortex, and these mice developed neurodegeneration and associated cognitive impairment related to macrophage/microglia activation (48, 50, 51 ). This mouse model has also been used to evaluate the efficacy of therapies to block HIV-1-induced neurological damage (49) . In another mouse model, used to study the pathogenesis of neuro-AIDS, transgenic mice expressing HIV-1 gp120 under the control of the GFAP promoter displayed neuronal and glial changes that resembled the abnormalities observed in the brains of HIV-1-infected humans (62) . To investigate the in vivo impact of HIV-1 infection on BBB compromise and the migration of HIV-1-infected monocytes across the BBB, we developed a novel in vivo mouse model consisting of mice transgenic both for the HIV-1 JR-CSF provirus populated with monocytes that produce infectious HIV-1 (13) and for the R26-EYFP transgene whose monocytes express EYFP. These double-transgenic mice provided a source of HIV-1-infected monocytes that can be readily detected by PCR and fluorescence microscopy in the brains of recipient mice after adoptive transfer. To determine whether HIV-1 infection increases the capacity of monocytes to migrate into the brain, we investigated whether JR-CSF mouse monocytes that support HIV-1 replication displayed an increased capacity to migrate across the intact BBB from the systemic circulation into the brain. While there was no detectable migration of monocytes from control R26-EYFP mice across the intact BBB, intravenously injected JR-CSF/EYFP monocytes that express HIV-1 proteins migrated across the intact BBB into some mouse brains. Nevertheless, few JR-CSF/EYFP monocytes initially crossed the intact BBB, as indicated by the requirement to perform two rounds of PCR to detect JR-CSF/EYFP monocytes carrying the HIV-1 provirus in the mouse brains. Production of HIV-1 proteins in infected monocytes may increase their capacity to cross the intact BBB by inducing upregulated expression of cellular adhesion molecules, which increases their adherence to microvascular endothelial cells. Another mechanism by which HIV-1 infection enables monocytes to cross the intact BBB may be related to the expression of surface gp120, which has been shown by in vitro studies to function as a weak lectin that facilitates adsorptive endocytosis (8) and to alter expression of tight junction proteins in brain endothelial cells (32) .
The capacity of HIV-1-infected monocytes to enter the brain was increased when the integrity of the BBB was partially compromised by the injection of LPS, particularly in the brains of JR-CSF mice, where the BBB is composed of cells carrying the HIV-1 provirus. The BBB in the JR-CSF mice was more sensitive to disruption by LPS than the BBB of control mice, indicating that HIV-1 infection may increase the sensitivity of the components that form the BBB to becoming compromised by systemic LPS. It is possible that increased susceptibility of the BBB in the JR-CSF mice that support HIV-1 replication to LPS treatment may be related to the capacity of HIV-1-infected monocytes to alter the brain microvascular proteome (56) . Our analysis of BBB function carried out by measuring the migration of monocytes from the systemic circulation into the brain was complemented by examination of the integrity of BBB proteins in the cerebral blood vessels. We demonstrated that LPS treatment more potently disrupted the tight junctions constituted by ZO-1 and occludin in the cerebral blood vessels of JR-CSF mice than did LPS treatment of control mice. In concert with increased compromise of the BBB, systemic LPS may stimulate monocyte migration into the brain by stimulating HIV-1-infected resident macrophages and microglia in the brain to secrete MCP-1, the chemokine that most potently induces migration of peripheral monocytes into the brain parenchyma (10) . We previously reported that LPS induced more MCP-1 production in vivo in JR-CSF mouse brains and in vitro FIG. 3 . Increased migration of JR-CSF/EYFP mouse monocytes into the brains of LPS-injected JR-CSF mice. JR-CSF mice and BALB/c mice were treated with LPS (3 mg/kg) and then intravenously injected with JR-CSF/EYFP monocytes (5 ϫ 10 6 cells). Four days later, DNA was extracted from the mouse brains, spleens, and peripheral blood leukocytes. PCR products amplified by a single round using primers specific for the EYFP gene or mouse exonuclease gene were resolved on an agarose gel containing ethidium bromide. Densitometric analysis of the EYFP-specific bands normalized to the exonuclease-specific bands was performed to determine the relative number of migrated monocytes. in JR-CSF mouse microglia than was the case with LPS-stimulated brains and microglia from control BALB/c mice (65) . Studies using an in vitro tissue culture BBB model demonstrated that HIV-1-infected monocytes are more responsive to MCP-1-mediated migration than uninfected monocytes (24) . Our demonstration that the intravenously injected JR-CSF/ EYFP monocytes were visualized in the parenchyma of the brain complemented our functional analysis of monocyte migration by PCR to confirm that HIV-1-infected monocytes transmigrated across the BBB and entered the parenchyma of the brain. The combination of compromising the BBB and inducing chemokine production that recruits monocytes into the brain may contribute to the increased migration of monocytes into the brains of LPS-injected JR-CSF mice compared to results with the brains of LPS-injected control mice. These complementary mechanisms may also be functioning in HIV-1-infected individuals to facilitate the migration of HIV-1-infected monocytes into their brains. Treatment with highly active antiretroviral therapy (HAART) has markedly reduced the incidence of neurological manifestations of HIV-1 infection (40) . Treatment with HAART also reduces the elevated systemic levels of LPS present in HIV-1-infected individuals (11) . An intriguing possibility is that HAART may lower the incidence of HAD not only by reducing HIV-1 replication but also by reducing systemic levels of LPS and thereby reducing compromise of the BBB and migration of HIV-1-infected monocytes from the systemic circulation into the brain. The results of this study demonstrate that carriage of the HIV-1 provirus by monocytes increased their ability to enter the brain, particularly after partial compromise of the BBB in response to LPS treatment, and indicate the applicability of these mice as an in vivo system to study the mechanism by which HIV-1-infected monocytes migrate into the brain and how these migrated cells subsequently cause CNS damage. A major advantage of our transgenic system is that it lends itself to application of the powerful tool of manipulating mouse genetics for the study of neuro-AIDS by crossing the JR-CSF mice with mice that either carry gene deletions or are transgenic for factors associated with passage of monocytes across the BBB, enabling us to identify genes whose expression plays a role in HIV-1-mediated disruption of the BBB. Furthermore, we plan to extend these studies to another transgenic mouse line we have generated, JR-CSF/hu-cycT1 mice, which display increased HIV-1 replication due to their capacity to support HIV-1 Tat function because of their transgenic expression of human cyclin T1 (61) . This in vivo mouse model would also permit examination of the capacities of various therapies to protect the BBB from compromise by determining the effects of candidate treatments on preventing or decreasing the migration of HIV-1-infected monocytes across the BBB. These future studies should contribute to our understanding of the role of the immune system and other in vivo factors in controlling traffic of HIV-1-infected monocytes across the BBB and their role in compromising subsequent BBB function.
